

BAXTER INTERNATIONAL INC.
Key Product Line Sales by US and International
Periods Ending March 31, 2008 and 2007
(unaudited)
(\$ in millions)

	Q1 2008			Q1 2007			% Growth		
	US	International	Total	US	International	Total	US	International	Total
BioScience									
Recombinants	\$199	\$237	\$436	\$179	\$209	\$388	11%	13%	12%
Plasma Proteins	92	168	260	88	137	225	5%	23%	16%
Antibody Therapy	199	87	286	159	63	222	25%	38%	29%
Regenerative Medicine ¹	47	47	94	43	39	82	9%	21%	15%
Other ²	10	124	134	15	140	155	(33%)	(11%)	(14%)
Total BioScience³	\$547	\$663	\$1,210	\$484	\$588	\$1,072	13%	13%	13%
Medication Delivery									
IV Therapies	\$111	\$260	\$371	\$101	\$219	\$320	10%	19%	16%
Global Injectables	200	168	368	227	134	361	(12%)	25%	2%
Infusion Systems	131	89	220	122	87	209	7%	2%	5%
Anesthesia	58	41	99	60	29	89	(3%)	41%	11%
Other	3	4	7	5	6	11	(40%)	(33%)	(36%)
Total Medication Delivery	\$503	\$562	\$1,065	\$515	\$475	\$990	(2%)	18%	8%
Renal									
PD Therapy	\$71	\$374	\$445	\$69	\$350	\$419	3%	7%	6%
HD Therapy	27	86	113	28	78	106	(4%)	10%	7%
Total Renal	\$98	\$460	\$558	\$97	\$428	\$525	1%	7%	6%
Baxter excluding Transfusion Therapies	\$1,148	\$1,685	\$2,833	\$1,096	\$1,491	\$2,587	5%	13%	10%
Transfusion Therapies⁴	\$31	\$13	\$44	\$43	\$45	\$88	(28%)	(71%)	(50%)
TOTAL BAXTER	\$1,179	\$1,698	\$2,877	\$1,139	\$1,536	\$2,675	4%	11%	8%

¹ Previously referred to as BioSurgery.

² Principally includes vaccines, sales of plasma to third parties, and recombinant FIX (BeneFIX). Sales of BeneFIX ceased as of June 30, 2007.

³ Prior year BioScience sales data has been reclassified as described in Note 4.

⁴ The TT business was sold on February 28, 2007. The results of operations of the TT business were previously reported in the BioScience business. The TT totals above include sales of TT products through the date of divestiture, as well as revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the TT business post-divestiture.